title: Olanzapine increases plasma ghrelin level in patients with schizophrenia.
abstract: OBJECTIVE
  Increased appetite and weight gain are frequently reported in treatment with olanzapine. However, the mechanism behind this appetite gain remains unclear. Ghrelin is a newly discovered appetite-stimulating peptide that has a role in the regulation of feeding behavior. Ghrelin is synthesized principally in the stomach, and the concentration of circulating ghrelin is negatively correlated with leptin and body fat mass. To elucidate the mechanism of appetite and weight gain during olanzapine treatment, we investigated the circulating ghrelin levels.
  
  
  METHODS
  Seven patients with schizophrenia were examined before and after 6-month administration of olanzapine. The concentrations of circulating ghrelin, leptin, glucose and lipid metabolic parameters were measured.
  
  
  RESULTS
  Body fat percentage (P=0.0121) and serum leptin (P=0.0284) were significantly increased after 6-month administration of olanzapine. Both plasma total ghrelin (P=0.0188) and active ghrelin levels (P=0.0057) were significantly increased. Six of the seven patients reported increased appetite during olanzapine treatment. Other glucose and lipid parameters were not altered significantly.
  
  
  CONCLUSIONS
  Although, the leptin level and body fat percentage were significantly increased, the concentration of circulating ghrelin was also significantly increased. Olanzapine may directly act on the secretion of ghrelin and induce appetite, resulting in weight gain.
authors.affiliation: Department of Psychiatry, Hokkaido University Graduate School of Medicine, North-14, West-7, Sapporo 060-8638, Japan. tm-mura@jb3.so-net.ne.jp
authors.forename: Mari
authors.initials: M
authors.lastname: Murashita
authors.forename: Ichiro
authors.initials: I
authors.lastname: Kusumi
authors.forename: Takeshi
authors.initials: T
authors.lastname: Inoue
authors.forename: Yoshito
authors.initials: Y
authors.lastname: Takahashi
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Hosoda
authors.forename: Kenji
authors.initials: K
authors.lastname: Kangawa
authors.forename: Tsukasa
authors.initials: T
authors.lastname: Koyama
mesh_terms: D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001066:Appetite / Q000187:drug effects; D001569:Benzodiazepines / Q000009:adverse effects* / Q000627:therapeutic use; D001823:Body Composition / Q000187:drug effects / Q000502:physiology; D015992:Body Mass Index; D001835:Body Weight / Q000187:drug effects / Q000502:physiology; D005260:Female; D054439:Ghrelin; D006801:Humans; D020738:Leptin / Q000097:blood; D008297:Male; D008875:Middle Aged; D000077152:Olanzapine; D036361:Peptide Hormones / Q000097:blood*; D011863:Radioimmunoassay; D012559:Schizophrenia / Q000097:blood* / Q000188:drug therapy; D015430:Weight Gain / Q000187:drug effects
chemical_list: D014150:Antipsychotic Agents; D054439:Ghrelin; D020738:Leptin; D036361:Peptide Hormones; D001569:Benzodiazepines; D000077152:Olanzapine